Apritant 150mg Injection

About

Apritant 150mg Injection contains aprepitant, a selective neurokinin-1 (NK1) receptor antagonist, primarily used for the prevention of chemotherapy-induced nausea and vomiting (CINV). It works by blocking the binding of substance P, a neuropeptide, to the NK1 receptors in the brainstem's chemoreceptor trigger zone and other areas involved in the emetic reflex. This action effectively prevents both acute and delayed phases of CINV, which are common and distressing side effects of highly emetogenic chemotherapy regimens. By targeting this specific pathway, Apritant provides a significant improvement in the control of nausea and vomiting, allowing patients to better tolerate their chemotherapy treatments and maintain a higher quality of life during their cancer therapy.

Uses

• Prevention of acute chemotherapy-induced nausea and vomiting.
• Prevention of delayed chemotherapy-induced nausea and vomiting.
• Used in combination with other antiemetics (e.g., corticosteroids, 5-HT3 antagonists).
• Management of nausea and vomiting associated with highly emetogenic chemotherapy.

Directions For Use

Administer intravenously as a single dose approximately 30 minutes before chemotherapy, as directed by a physician.

Benefits

• Effectively prevents both acute and delayed CINV.
• Targets a distinct pathway for antiemetic action.
• Significantly improves patient comfort during chemotherapy.
• Reduces the incidence and severity of nausea and vomiting.
• Allows better adherence to chemotherapy regimens.
• Enhances overall quality of life for cancer patients.

Side Effects

• Fatigue
• Dizziness
• Headache
• Hiccups
• Constipation
• Diarrhea
• Loss of appetite
• Abdominal pain
• Weakness
• Injection site reactions
• Elevated liver enzymes
• Hypersensitivity reactions (rare)

Safety Measures

• Alcohol - No specific interaction, but alcohol may exacerbate nausea or fatigue.
• Pregnancy - Use only if clearly needed and the potential benefits outweigh the risks. Consult a physician.
• Breastfeeding - Exercise caution; it is unknown if aprepitant is excreted in human milk. Consult a physician.
• Liver - Use with caution in patients with severe hepatic impairment; monitor closely.
• Kidney - No dose adjustment is typically required for patients with renal impairment.
• Lung - No specific precautions for lung conditions.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.